文献速递免疫规划慢病防控与筛查妇幼与学校卫生

美国加利福尼亚州阿拉米达县高级别宫颈上皮内瘤变(CIN2/3/AIS)女性中四价和非价HPV疫苗型别的种族/民族及社会人口学因素分布

Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States.
PubMed 文献 · Vaccine · 2019-10-11

基于阿拉米达县2008-2015年1810例CIN2/3/AIS宫颈组织标本的监测数据,分析四价疫苗型别(16/18)和非价疫苗型别(31/33/45/52/58)的种族/民族差异。调整保险、年龄、病变级别和时间段后,黑人(43%)和西班牙裔(43%)女性HPV16/18检出率显著低于白人(52%),aPR分别为0.80(95%CI 0.70-0.93)和0.80(95%CI 0.70-0.91)。非价疫苗型别在西班牙裔女性调整后显著高于白人(32% vs 27%,aPR 1.22,95%CI 1.02-1.47)。

要点

  • 2008-2015年CIN2/3/AIS标本中,黑人(43%)和西班牙裔(43%)女性HPV16/18检出率低于白人(52%),aPR均为0.80。
  • 2008-2011年黑人(47%)、西班牙裔(46%)、亚裔(42%)女性HPV16/18检出率均显著低于白人(58%);2012-2015年无显著差异。
  • 调整后西班牙裔女性HPV31/33/45/52/58检出率(32%)显著高于白人(27%),aPR 1.22(95%CI 1.02-1.47)。

核心结论

  • 白人、黑人和西班牙裔女性CIN2/3/AIS病变中HPV16/18检出率下降可能提示四价疫苗受益。
  • 非价疫苗对宫颈癌前病变的潜在影响在少数族裔女性中不会低于白人女性。
  • 数据强调公平接种疫苗对促进所有女性疫苗可预防HPV型别持续下降的重要性。

研究设计与样本

  • 分析HPV-IMPACT(美国加利福尼亚州阿拉米达县)基于人群的CIN2/3/AIS监测中1810例宫颈组织标本的HPV分型数据,时间段为四价HPV疫苗引入后2008-2015年。
  • 采用对数二项回归计算调整患病率比(aPR)及95%置信区间(CI),调整健康保险、年龄、CIN2/3/AIS级别和时间段。
  • 分析覆盖总体以及「早期疫苗时代」(2008-2011年)和「后期疫苗时代」(2012-2015年)。

主要发现

  • 总体致癌HPV16/18患病率黑人43% vs 白人52%(aPR 0.80,95%CI 0.70-0.93),西班牙裔43% vs 白人52%(aPR 0.80,95%CI 0.70-0.91),均显著更低。
  • 2008-2011年HPV16/18检出比例黑人47% vs 白人58%(aPR 0.80,95%CI 0.67-0.96),西班牙裔46% vs 白人58%(aPR 0.75,95%CI 0.63-0.90),亚裔42% vs 白人58%(aPR 0.73,95%CI 0.58-0.90),均显著更低;2012-2015年无显著差异。
  • 两个时代之间,HPV16/18患病率白人下降11%、黑人下降9%、西班牙裔下降6%,亚裔上升12%。
  • 未调整分析中HPV31/33/45/52/58患病率种族/民族间无显著差异;调整后西班牙裔32% vs 白人27%(aPR 1.22,95%CI 1.02-1.47)显著更高。
  • 调整后黑人32%和亚裔33%女性HPV31/33/45/52/58患病率较白人非显著升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We evaluated racial/ethnic differences in prevalence of oncogenic HPV types targeted by the quadrivalent HPV vaccine (16/18) and nonavalent HPV vaccine (31/33/45/52/58) in women diagnosed with CIN2/3/AIS after quadrivalent HPV vaccine introduction (2008-2015). Typing data from 1810 cervical tissue specimen from HPV-IMPACT (Alameda County, California, US), a population-based CIN2/3/AIS surveillance effort, were analyzed. Using log-binomial regression, we calculated adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) comparing type prevalence by race/ethnicity, adjusted for health insurance, age, CIN2/3/AIS grade, and time period, overall and in the "early vaccine era" (2008-2011) and "later vaccine era" (2012-2015). Overall, oncogenic HPV16/18 prevalence was significantly lower among black (43%) and Hispanic (43%) women compared with white (52%) women (aPR (95% CI): 0.80 (0.70, 0.93) and 0.80 (0.70, 0.91), respectively). In 2008-2011, proportion of HPV16/18 detected was significantly lower in black (47%), Hispanic (46%), and Asian (42%) women compared to white (58%) women (aPR (95% CI): 0.80 (0.67, 0.96), 0.75 (0.63, 0.90), and 0.73 (0.58, 0.90), respectively). There were no significant differences in 2012-2015. Between the two eras, HPV16/18 prevalence declined in white (-11%), black (-9%), and Hispanic (-6%) women, and increased in Asian women (12%). Decreasing HPV 16/18 prevalence in CIN2/3/AIS lesions in white, black, and Hispanic women may suggest benefit from quadrivalent vaccination. In our unadjusted analysis of HPV31/33/45/52/58, prevalence did not differ significantly by race/ethnicity, but was significantly higher among Hispanic women (32%) compared to white women (27%) after adjustment (aPR (95%CI): 1.22 (1.02, 1.47). Prevalence was also non-significantly higher among black (32%) and Asian (33%) women. This analysis suggests that the nonavalent vaccine's potential for impact against cervical precancers will not be lower in women of color compared to white women. These data underscore the importance of equitable vaccination in facilitating continued declines of vaccine-preventable HPV types among all women.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Saadeh K, Park I, Gargano JW, et al. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States. Vaccine. 2019. PMID: 31611099. doi:10.1016/j.vaccine.2019.09.103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。